US 12,458,534 B2
Eye stents and delivery systems
Anand Doraiswamy, Oakland, CA (US)
Assigned to Aquea Health, Inc., Hillsborough, CA (US)
Filed by Aquea Health, Inc., San Francisco, CA (US)
Filed on Jan. 5, 2022, as Appl. No. 17/569,329.
Application 17/569,329 is a continuation in part of application No. PCT/US2020/041704, filed on Jul. 10, 2020.
Claims priority of provisional application 62/945,160, filed on Dec. 8, 2019.
Claims priority of provisional application 62/874,946, filed on Jul. 16, 2019.
Claims priority of provisional application 62/872,494, filed on Jul. 10, 2019.
Prior Publication US 2022/0142817 A1, May 12, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61F 9/007 (2006.01)
CPC A61F 9/00781 (2013.01) [A61F 2210/0014 (2013.01); A61F 2250/0067 (2013.01)] 65 Claims
OG exemplary drawing
 
1. A method of treating glaucoma in a patient, comprising:
implanting an expansion member consisting of a single elongated element in a channel of an uveolymphatic region or a Schlemm's canal of the patient; and
implanting the single elongated element under conditions such that no significant deforming forces are transmitted to the Schlemm's canal;
wherein the single elongated element opens the channel with (i) sufficient radial strength to withstand compressive stresses exerted by the channel and (ii) sufficient void space in its structure to minimize blockage of collector channels in the channel when the expansion member is implanted in the channel.